

Cutaneous Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C1C6A433C7ABEN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: C1C6A433C7ABEN

Abstracts

The 7 major cutaneous squamous cell carcinoma markets reached a value of US\$ 7.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 13.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.01% during 2024-2034.

The cutaneous squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Cutaneous Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cutaneous squamous cell carcinoma (cSCC) refers to a type of skin cancer that arises from squamous cells, which are thin, flat cells found in the outermost layer of the skin (epidermis). This ailment typically develops in regions that are exposed to the sun, like the ears, face, lips, scalp, neck, hands, arms, etc.; however, it can also occur in different areas of the body. The most common symptom of cSCC is the presence of a persistent, non-healing skin lesion or soreness. It may start as a small, firm, red nodule or a scaly patch of skin that gradually grows over time. Individuals suffering from this disease may also experience itching or tenderness in the impacted area, along with ulceration and bleeding. The diagnosis of the condition generally requires a combination of clinical examination, biopsy, and histopathological analysis. The healthcare provider will initially visualize the affected region of the skin to check for any indicative signs of cSCC, including a raised, firm, or scaly growth. Numerous imaging techniques, like ultrasound and computed tomography scans, are utilized to detect the extent of cancer in patients.

The increasing cases of chronic exposure to ultraviolet rays from the sun or artificial sources, including tanning beds, are primarily driving the cutaneous squamous cell carcinoma market. In addition to this, the growing incidences of various associated risk

factors, including fair skin, advancing age, a weakened immune system, genetic disorders, etc., are further bolstering the market growth. Moreover, the widespread adoption of effective topical chemotherapy or immunotherapy creams since they can be directly applied to the affected site for specific disruption of cancerous cells or tissues is also acting as a significant growth-inducing factor. Besides this, the escalating utilization of minimally invasive photodynamic therapy that combines the application of a photosensitizing agent and light to destroy tumors is further creating a positive outlook for the market. Additionally, the emerging popularity of cryotherapy owing to its various advantages over surgical excisions, such as precise targeting and quick recovery time with minimum damage to surrounding healthy tissue, is expected to drive the cutaneous squamous cell carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cutaneous squamous cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cutaneous squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cutaneous squamous cell carcinoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the cutaneous squamous cell carcinoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cutaneous squamous cell carcinoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cutaneous squamous cell carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the cutaneous squamous cell carcinoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cutaneous squamous cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cutaneous squamous cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cutaneous squamous cell carcinoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of cutaneous squamous cell carcinoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cutaneous squamous cell carcinoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cutaneous squamous cell carcinoma across the seven major markets?

What is the size of the cutaneous squamous cell carcinoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cutaneous squamous cell carcinoma?

What will be the growth rate of patients across the seven major markets?

Cutaneous Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cutaneous squamous cell carcinoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cutaneous squamous cell carcinoma market?

What are the key regulatory events related to the cutaneous squamous cell carcinoma market?

What is the structure of clinical trial landscape by status related to the cutaneous squamous cell carcinoma market?

What is the structure of clinical trial landscape by phase related to the cutaneous squamous cell carcinoma market?

What is the structure of clinical trial landscape by route of administration related to the cutaneous squamous cell carcinoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CUTANEOUS SQUAMOUS CELL CARCINOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CUTANEOUS SQUAMOUS CELL CARCINOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CUTANEOUS SQUAMOUS CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 CUTANEOUS SQUAMOUS CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CUTANEOUS SQUAMOUS CELL CARCINOMA - UNMET NEEDS

10 CUTANEOUS SQUAMOUS CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT

11 CUTANEOUS SQUAMOUS CELL CARCINOMA - MARKETED PRODUCTS

- 11.1 List of Cutaneous Squamous Cell Carcinoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Keytruda (Pembrolizumab) - Merck & Co
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CUTANEOUS SQUAMOUS CELL CARCINOMA - PIPELINE DRUGS

12.1 List of Cutaneous Squamous Cell Carcinoma Pipeline Drugs Across the Top 7 Markets

- 12.1.1 STP 705 - Sirnaomics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 ASP-1929 - Rakuten Medical
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 RM-1995 - Rakuten Medical
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 NT-I7 - NeoImmuneTech
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the

complete list has been provided in the report.

13. CUTANEOUS SQUAMOUS CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CUTANEOUS SQUAMOUS CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 CUTANEOUS SQUAMOUS CELL CARCINOMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Cutaneous Squamous Cell Carcinoma - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Cutaneous Squamous Cell Carcinoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Cutaneous Squamous Cell Carcinoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Cutaneous Squamous Cell Carcinoma - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Cutaneous Squamous Cell Carcinoma - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Cutaneous Squamous Cell Carcinoma - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Cutaneous Squamous Cell Carcinoma - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Cutaneous Squamous Cell Carcinoma - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Cutaneous Squamous Cell Carcinoma - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Cutaneous Squamous Cell Carcinoma - Access and Reimbursement Overview

16 CUTANEOUS SQUAMOUS CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CUTANEOUS SQUAMOUS CELL CARCINOMA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 CUTANEOUS SQUAMOUS CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Cutaneous Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C1C6A433C7ABEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1C6A433C7ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

